<PAGE>

================================================================================

                                 UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                 -------------

                                 FORM 10-Q/A-1

(Mark One)

[X]  Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934

For the period ended September 30, 1999

                                      OR

[_]  Transition report pursuant to Section 13 or 15(d) of the Securities
     Exchange Act of 1934


                       Commission file number: 000-29282

                             MEDICONSULT.COM, INC.
--------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)

        DELAWARE                                      84-1341886
        --------                                      ----------
(State or other jurisdiction of            (I.R.S. Employer Identification No.)
incorporation or organization)

                    1330 Avenue of the Americas, 17th Floor
                              New York, NY 10019
         ------------------------------------------------------------
         (Address of principal executive offices, including zip code)

        Registrant's Telephone No., including area code: (212) 841-7300

         ------------------------------------------------------------


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.  Yes  X    No ___
                                        ---

As of October 12, 1999, there were approximately 28,974,603 shares of the
Registrant's Common Stock outstanding.

================================================================================
<PAGE>

                                     INDEX




PART I.  FINANCIAL INFORMATION

<TABLE>
<CAPTION>
                                                                                         PAGE
<S>                                                                                      <C>
Item 1.   Financial statements

          Unaudited Consolidated Balance Sheets - September 30, 1999 and December
          31, 1998                                                                         3

          Unaudited Consolidated Statement of Operations - Three and Nine Months
          Ended September 30, 1999 and 1998                                                4

          Unaudited Consolidated Statement of Cash Flows - Nine Months Ended
          September 30, 1999 and 1998                                                      5

          Notes to Unaudited Consolidated Financial Statements                             6

Item 2.   Management's Discussion and Analysis of Financial Condition and Results
          of Operations                                                                    8

PART II.  OTHER INFORMATION                                                               19

Item 1.   Pending Legal Proceedings                                                       19

Item 2.   Changes in Securities                                                           19

Item 4.   Submission of Matters to a Vote of Security Holders                             19

Item 6.   Exhibits and Reports Filed on Form 8-K                                          19
</TABLE>

PART I.

FINANCIAL INFORMATION

EXPLANATORY NOTE: Pursuant to this form 10-Q/A, Mediconsult.com, Inc. amends
"Item 1. FINANCIAL STATEMENTS", and ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS" of part I of its Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 1999.


ITEM 1.   FINANCIAL STATEMENTS

The financial statements for the quarter ended September 30, 1999 have been
revised from amounts previously reported to report higher revenues as well as
higher operating expenses, the write-off of amounts capitalized in conjunction
with Pharma Marketing LLC, as well as increased costs in connection with the
accounting for stock options in the third quarter of 1999. The Company also
recorded a preferred stock dividend during the quarter ended March 31, 1999.
<PAGE>

Mediconsult.com, Inc.
Unaudited Consolidated Balance Sheets - September 30, 1999 and December 31, 1998
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                           September 30    December 31
                                                                               1999           1998
                                                                           ------------   -------------
                                                                           (As revised
                                                                           see Note 10)
<S>                                                                        <C>            <C>
            ASSETS
Current assets
   Cash and cash equivalents                                               $ 33,927,596   $     135,053
   Accounts receivable                                                          545,560         135,790
   Un-billed Revenue                                                          1,812,100               -
   Prepaid expenses and other current assets                                    397,322               -
                                                                           ------------   -------------
   Total current assets                                                      36,682,578         270,843

   Fixed assets, net                                                          1,185,947          52,790
   Advance to Physicians' Online, Inc.                                       10,096,438               -
   Intangible assets, net                                                    10,812,315         818,750
                                                                           ------------   -------------
Total assets                                                               $ 58,777,278   $   1,142,383
                                                                           ============   =============

     LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
   Accounts payable and accrued expenses                                      2,218,378         243,413
   Advances from Shareholder                                                          -         513,589
   Deferred revenue                                                                   -         107,000
                                                                           ------------   -------------
   Total current liabilities                                                  2,218,378         864,002
                                                                           ------------   -------------

Commitments and contingencies                                                        --              --

Mandatorily redeemable
    Senior preferred stock, $0.001 par value, 1,000,000
    authorized, nil shares outstanding at September 30, 1999
    and December 31, 1998                                                            --              --
                                                                           ------------   -------------

Stockholders' equity
 Preferred stock
    Junior preferred stock, 1,000,000 shares designated,
    Nil and 430,000 shares issued and outstanding at September 30,
    1999 and December 31, 1998, respectively                                         --       4,300,000

 Common stock, $.001 par value, 50,000,000 shares authorized,
 28,721,163 and 18,519,950 shares issued and outstanding at
 September 30, 1999 and December 31, 1998, respectively                          28,721          18,520

 Additional paid-in capital                                                  88,170,156       5,242,981
 Deferred compensation                                                       (8,327,636)       (884,109)
 Accumulated deficit                                                        (23,312,341)     (8,399,011)
                                                                           ------------   -------------
 Total stockholders' equity                                                  56,558,900         278,381
                                                                           ------------   -------------
Total liabilities and stockholders' equity                                 $ 58,777,278   $   1,142,383
                                                                           ============   =============
</TABLE>

                            See accompanying notes.

<PAGE>

Mediconsult.com, Inc.
Unaudited Consolidated Statement of Operations for the Three and Nine Months
Ended September 30, 1999 and 1998
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                    Three Months Ended             Nine Months Ended
                                                              ------------------------------ -----------------------------
                                                              September 30,    September 30, September 30,   September 30,
                                                                  1999            1998          1999            1998
                                                              -------------    ------------- -------------   -------------
                                                              (As Revised                     (As Revised
                                                              see Note 10)                    see Note 10)
<S>                                                           <C>              <C>           <C>             <C>

Revenues                                                       $ 2,416,012     $   238,203   $   3,715,432   $    658,972
                                                               -----------     -----------   -------------   ------------
Operating Expenses:
  Product and content development                                2,368,609         400,693       4,641,565        911,085
  Marketing, sales and client services                           6,087,397         234,153       7,661,904        914,289
  General and administrative                                     1,846,665         183,969       3,332,837        491,957
  Depreciation and amortization                                    885,339          44,504       1,392,204        209,920
  Fair value of options granted to employees                       517,183          26,097       1,060,949         95,406
  Fair value of warrants granted to third parties                  209,942               -       1,707,611              -
                                                               -----------     -----------   -------------   ------------
  Total Operating Expenses                                      11,915,135         889,416      19,797,070      2,622,657
                                                               -----------     -----------   -------------   ------------
Loss from operations                                            (9,499,123)       (651,213)    (16,081,638)    (1,963,685)
Interest income                                                    592,272               -       1,168,308              -
                                                               -----------     -----------   -------------   ------------
Net loss                                                       $(8,906,851)    $  (651,213)  $ (14,913,330)  $ (1,963,685)
Dividends on preferred stock                                             -               -         945,505              -
Net loss attributable to common shareholders                   $(8,906,851)    $  (651,213)  $ (15,858,835)  $ (1,963,685)
                                                               ===========     ===========   =============   ============

Net loss per share - basic and fully diluted                   $     (0.31)    $     (0.04)  $       (0.64)  $      (0.11)
                                                               ===========     ===========   =============   ============
Weighted average shares of common stock outstanding
 used in computing basic and diluted net
 loss per share                                                 28,559,488      18,097,400      24,882,258     17,763,525
                                                               ===========     ===========   =============   ============
</TABLE>

                            See accompanying notes.
<PAGE>

Mediconsult.com, Inc.
Unaudited Consolidated Statement of Cash Flows for the Nine Months Ended
September 30, 1999 and 1998
--------------------------------------------------------------------------------

<TABLE>
<CAPTION>
                                                                                   Nine Months Ended
                                                                             ------------------------------
                                                                             September 30,   September 30,
                                                                                  1999            1998
                                                                             --------------  --------------
                                                                              (As Revised
                                                                              see Note 10)
<S>                                                                          <C>             <C>
Cash flows from operating activities
Net loss                                                                      $(14,913,330)    $(1,963,685)
Adjustment to reconcile net loss to net cash used in operating activities
 Depreciation of fixed assets                                                      389,586         209,920
 Amortization of intangible assets                                               1,002,618               -
 Amortization of deferred compensation related to shares issued
  for services and membership interest in Pharma Marketing LLC                   1,219,280               -
 Fair value of options and warrants granted                                      2,768,560               -
 Changes in assets and liabilities
  Accounts receivable                                                             (278,000)       (242,312)
  Un-billed revenue                                                             (1,812,100)              -
  Prepaid expenses and other current assets                                       (397,322)              -
  Accounts payable and accrued expenses                                          1,818,746          67,306
  Deferred revenue                                                                (107,000)              -
                                                                              ------------     -----------
Net cash used in operating activities                                          (10,308,962)     (1,928,771)
                                                                              ------------     -----------

Cash flows from investing activities
 Fixed assets purchases                                                         (1,511,414)        (30,225)
 Acquisition of subsidiaries                                                    (4,127,343)              -
 Advance to Physicians' Online, Inc.                                           (10,096,438)              -
                                                                              ------------     -----------
Net cash used in investing activities                                          (15,735,195)        (30,225)
                                                                              ------------     -----------

Cash flows from financing activities
 Proceeds from advances from shareholder                                           315,000              --
 Repayment of advances from shareholder                                           (828,599)       (130,499)
 Proceeds from issuance of senior preferred stock                                3,160,000              --
 Proceeds from issuance of junior preferred stock                                       --       1,800,000
 Proceeds from exercise of warrants                                                111,353              --
 Proceeds from issuance of common stock in a secondary offering,
  net of issuance cost of $5,411,208                                            56,988,792              --
 Proceeds from exercise of stock options                                            90,154             600
                                                                              ------------     -----------
Net cash provided by financing activities                                       59,836,700       1,670,101
                                                                              ------------     -----------

(Decrease) increase in cash                                                     33,792,543        (288,895)

Cash - beginning of period                                                         135,053         400,949
                                                                              ------------     -----------

Cash - end of period                                                          $ 33,927,596     $   112,054
                                                                              ============     ===========
</TABLE>

                            See accompanying notes.
<PAGE>

                             MEDICONSULT.COM, INC.
             NOTES TO CONDENSED CONSOLIDATED FINANCING STATEMENTS
                                  (Unaudited)

Unless otherwise noted, references to "we," "our," and "us" refer to Mediconsult
and its subsidiaries.

1.   ORGANIZATION

Mediconsult.com, Inc. (the "Company" or "Mediconsult") was originally
incorporated under the laws of the State of Colorado in October 1989. In April
1996, we purchased Mediconsult.com Limited, a Bermuda corporation ("MCL"),
through a merger in which MCL became a wholly-owned subsidiary, resulting in 90%
of the outstanding stock of Mediconsult being held by the former stockholders of
MCL, The Mediconsult Trust, controlled by Mr. Robert Jennings, and Michel
Bazinet. In December 1996, we consummated a re-incorporation merger pursuant to
which Mediconsult became a Delaware corporation. We conduct business primarily
through MCL and two other operating subsidiaries, Mediconsult.com (US), Ltd. and
3542491 Canada Inc. d/b/a Mediconsult.com Canada.

Mediconsult is a provider of patient-oriented healthcare information and
services on the World Wide Web. Our sites provide a source of medical
information and are designed to empower consumers through increased consumer
education regarding medical conditions and treatment alternatives. These sites
also provide a destination on the Internet where visitors can interact with
others in communities centered around chronic medical conditions and other
health issues. We facilitate this environment through an array of complementary
services such as moderated on-line support groups and discussion forums.

2.   BASIS OF PRESENTATION

These condensed consolidated financial statements are unaudited and reflect all
adjustments that, in our opinion, are necessary for a fair presentation of the
results for the interim period. The results of operations for the current
interim period are not necessarily indicative of results to be expected for the
current year or any other period. Certain amounts have been reclassified to
conform to the fiscal 1999 presentation.

These consolidated financial statements should be read in conjunction with the
consolidated financial statements and notes thereto included in our S-1
registration statement as filed with the Securities and Exchange Commission.

3.   UN-BILLED REVENUE

Un-billed revenue represents the value of development work completed but not
billed at September 30, 1999.

4.   ACQUISITIONS

     On September 7, 1999, the Company entered into an agreement to acquire the
shares of Physicians' Online, Inc. ("POL"), a provider of an exclusive network
for physicians in addition to on-line medical information and communications.
POL operates a secure, physicians-only environment featuring access to medical
databases, daily medical news, continuing medical education credits, clinical
symposia, e-mail accounts, Internet access, and other services. Consideration
for the acquisition will be up to 20 million shares of Mediconsult common stock.
The total transaction value at the time of announcement was $180 million,
including the assumption of debt. The transaction is subject to customary
closing conditions. The stockholders of Physicians' Online, Inc. and Mediconsult
hold the votes required to approve the merger and have agreed to vote in favor
of the transaction. In the quarter ended September 30, 1999, the Company
advanced $10.1 million to Physicians' Online, Inc. This advance bears interest
at rates between 12% and 14%.

5.   PHARMA MARKETING LLC

On September 7, 1999 the Company entered into a membership investment agreement
for the purchase 35% of the aggregate membership interests of Pharma Marketing
LLC ("Pharma") for $1.25 million and 200,000 shares of Mediconsult common stock.
The remaining 65% of Pharma is owned by a certain individual ("Individual").
Under the terms of an operating agreement with and among Mediconsult, Pharma and
the Individual, the $1.25 million contributed by the Company and 100,000 of the
200,000 shares that the Company issued to Pharma, were distributed to the
Individual in September 1999. For financial reporting purposes, all costs
associated with Pharma are included in Marketing, Sales and Client Services in
the consolidated statement of operations. During the quarter ended 1999, such
Pharma expenses amounted to $3.32 million.

Mediconsult.com, Limited, a subsidiary of the Company, has entered into a
service agreement with Pharma under which Pharma agrees to provide
pharmaceutical sales and marketing services to Mediconsult.com, Limited and its
affiliates. Under this
<PAGE>

service agreement, Pharma is entitled to receive a monthly retainer and
commissions based on revenues generated under contracts that Pharma assists in
obtaining. Pharma entered into an employment agreement with the Individual,
under which, the Individual is principally responsible for performing the
services under Pharma's service agreement with Mediconsult.com, Limited.

Subject to certain conditions described in the operating agreement, the members
of Pharma, other than Mediconsult, have the right to put their Pharma membership
interests to the Company in exchange for 600,000 shares of the Company's common
stock.

6.   STOCK OPTIONS

We have a 1996 Stock Option Plan (the "Plan") to provide incentives to
employees, directors and consultants. The maximum term of options granted under
the Plan is ten years. The Board of Directors has the exclusive power over the
granting of options and their vesting provisions. Stock options for common stock
comprise:

<TABLE>
<CAPTION>
                                                        1999
                                              --------------------------
                                                  #       Weighted Avg.
                                                Shares    Exercise Price
                                              ----------  --------------
<S>                                           <C>         <C>
Outstanding - December 31, 1998               2,716,000          0.37
Granted during the period                     1,044,800         10.13
Exercised during the period                    (201,900)         1.53
Cancelled during the period                     (49,400)         3.14
                                              ---------         -----
Outstanding - September 30, 1999              3,509,500          3.15
                                              ---------         -----
Exercisable - September 30, 1999              2,527,000          0.37
                                              ---------         -----
</TABLE>

During the three months ended September 30, 1999 and 1998 the fair values of the
options granted to employees were $517,183 and $26,097, respectively.

7.   WARRANTS

On August 1, 1998, we granted 400,000 warrants to Arnhold and S. Bleichroeder,
Inc., which were issuable upon meeting certain criteria related to investment
advisory fees and exercisable at $1.22 per share. These warrants expire on July
28, 2003 and have cash-less exercise provisions and anti-dilution provisions
comparable to the senior preferred stock warrants. These warrants vested or vest
in tranches as follows: 200,000 shares upon filing a registration statement on
form S-1; 100,000 shares on March 15, 2000; and 100,000 shares on September 15,
2000. The warrants vesting in 2000 are subject to continued performance of
financial advisory services by a particular individual on behalf of Arnhold and
S. Bleichroeder.  During the quarter and six months ended September 30, 1999,
the Company recognized expenses of $0.2 million and $1.7 million, respectively,
related to the fair value of these warrants.

On February 26, 1999, the Company sold in a private placement an aggregate of
506,329 shares of newly designated voting senior preferred stock at $6.32 per
share and warrants exercisable for five years to purchase 224,000 shares of the
senior preferred stock at $6.32 per share to Nazem & Company IV, L.P.
Transatlantic Venture Fund C.V. (a joint venture of Nazem & Company and Banque
Nationale de Paris) and certain other individual investors, for an aggregate of
$3.2 million. The senior preferred stock contains a redemption provision
whereby the holder has the option to receive $6.32 per share, plus declared and
unpaid dividends, at any time after February 25, 2003. In addition, the Company
has recognized a senior preferred stock dividend of approximately $859,000. Such
amount represents the intrinsic value of the beneficial conversion to the
holders. During April 1999, all shares of senior preferred stock and accumulated
dividends were converted into an equal number of common shares. As of September
30, 1999, the 224,000 warrants remain outstanding, however, such warrants are
convertible into an equal number of shares of common stock.

<PAGE>

8.   RELATED PARTY TRANSACTIONS

During the three months ended September 30, 1999, we repaid net advances from
shareholders of $314,989 and an employee repaid an advance of $32,550 made in
June 1999 to fund the purchase of shares under our stock option plan.

During the three months ended September 30, 1999, we paid or accrued sales and
marketing expenses of $425,697 in respect of Pharma Marketing, LLC. (see Note 5
above), and advanced $10,096,438 to Physicians' Online, Inc.

9.   SUBSEQUENT EVENTS

Mood Sciences, a company that specializes in mental health disease management
innovations, was acquired in a transaction completed on October 27, 1999 in
exchange for 200,000 shares of Mediconsult common stock. The 200,000 shares is
subject to increase by 15,000 shares based upon the closing price of Mediconsult
common stock for the 20 trading days ending February 1, 2000. The excess of the
purchase price over net assets acquired will be recorded as goodwill and be
amortized on a straight-line basis over five years.

10.  REVISION

Prior to the issuance of the Company's financial statement for the year ended
December 31, 1999 management determined that the following items were
inaccurately recorded in the third quarter of 1999:
<TABLE>
<CAPTION>
                                                         Effect on Net Loss
                                                 Attributable to Common Shareholders
                                                        (Increase)/Decrease
                                                 -----------------------------------
                                                 Quarter Ended     Nine Months Ended
                                                    09/30/99            09/30/99
                                                 -----------------------------------
<S>                                              <C>                  <C>
Increase in (reduction of) revenue               $     431,756        $  (172,400)
Reflect the beneficial conversion on
  preferred stock                                           --           (945,505)
Fair value of options granted to employees             602,874            634,476
Fair value of warrants granted to consultants         (209,942)           561,493
Expense amounts related to Pharma Marketing LLC     (3,322,956)        (3,322,956)
Other net decrease in operating expenses              (621,581)          (785,963)
                                                 --------------------------------

  Total effect                                   $  (3,119,849)       $(4,030,855)
                                                 ================================
</TABLE>

Other adjustments included the reclassification of senior preferred stock to the
mezzanine section of the balance sheet and the increase of deferred compensation
related to stock options granted but not yet vested by $654,445.

A summary of the effects of the revisions on the balance sheets and statements
of operation is as follows:

<TABLE>
<CAPTION>
                                                                                             For the Nine
                                                   For the Quarter Ended                     Months Ended
                                                    September 30, 1999                    September 30, 1999
                                              -----------------------------          ------------------------------
                                                              As Previously                          As Previously
                                              As Revised         Reported            As Revised        Reported
                                              ----------     --------------          ----------      --------------

<S>                                           <C>             <C>                    <C>             <C>
Cash and cash equivalents                                                             33,927,596      33,947,811
Un-billed revenue                                                                      1,812,100       2,241,850
Prepaid expenses and other                                                               397,322         905,720
Total current assets                                                                  36,682,578      37,640,941
Intangible assets                                                                     10,812,315      13,873,866
Total assets                                                                          58,777,278      62,797,192
Accounts payable and accrued liabilities                                               2,218,378       1,956,973
Total liabilities                                                                      2,218,378       1,956,973
Additional paid in capital                                                            88,170,156      90,020,570
Deferred compensation                                                                 (8,327,636)     (8,982,081)
Retained deficit                                                                     (23,312,341)    (20,226,991)
Total stockholders' equity                                                            56,558,900      60,840,219
Total liabilities and stockholders' equity                                            58,777,278      62,797,192
</TABLE>

<PAGE>

<TABLE>
<S>                                                        <C>           <C>              <C>             <C>
Revenues                                                    2,416,012     1,984,256         3,715,432       3,887,832
General and administrative                                  1,846,665     1,225,084         3,332,837       2,546,874
Marketing, sales and client services                        6,087,397     2,764,441         7,661,904       4,338,948
Fair value of options granted to employees                    517,183     1,120,057         1,060,949       1,695,425
Fair value of warrants granted to third parties               209,942             -         1,707,611       2,269,104
Total operating expenses                                   11,915,135     8,363,530        19,797,070      16,884,120
Loss from operations                                       (9,499,123)   (6,379,274)      (16,081,638)    (12,996,288)
Net loss                                                   (8,906,851)   (5,787,002)      (14,913,330)    (11,827,980)
Preferred shares dividend                                           -             -           945,505               -
Net loss attributed to common shareholders                 (8,906,851)   (5,787,002)      (15,858,835)    (11,827,980)
Net loss per common chare - basic                               (0.31)        (0.20)            (0.64)          (0.48)
</TABLE>

ITEM 2.   MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
          RESULTS OF OPERATIONS

Unless otherwise noted, references to "we," "our," and "us" refer to Mediconsult
and its subsidiaries.

OVERVIEW

Mediconsult is a leading provider of patient-oriented healthcare information and
services on the World Wide Web. Our Web sites provide a trusted source of
comprehensive and easy to understand medical information and are designed to
empower consumers through increased education related to medical conditions and
treatment alternatives. The Web sites also provide a destination on the Internet
where visitors can interact with others in a community environment. We
facilitate this environment through a well-organized, easy to navigate format
and an array of complementary services, including moderated on-line support
groups and discussion forums. By fostering communities centered around over 60
prevalent chronic medical conditions and health issues, we believe that
Mediconsult creates significant opportunities for pharmaceutical and other
healthcare companies to reach a highly targeted consumer audience using
Internet-based marketing and advertising programs.

BACKGROUND

For the period from the inception of our operations in April 1996 through
January 1997, our operating activities related primarily to the initial
development of the mediconsult.com Web site and operating infrastructure, and
also the recruitment of employees. Since the launch of mediconsult.com in 1996,
we have focused on developing and organizing content in an easy to navigate
format, and improving the functionality of mediconsult.com. We have added new
sites through subsequent acquisitions including cyberdiet.com and heartinfo.com,
and new Internet-based healthcare tools through the acquisition of Mood
Sciences. We continue to refine our strategy of creating targeted on-line
marketing and advertising programs for large pharmaceutical and other healthcare
organizations. We continue to develop and implement these types of programs for
our clients. We structure our programs to provide advertisers with a measurable
return on their investment by tracking the level of interest and interactive
responses of visitors. Our programs utilize a broad range of on-line strategies
and resources to deliver a message consistent with the advertisers' global
marketing strategy.

In the third quarter we expanded our focus on long-term strategic relationships
with major pharmaceutical manufacturers to include other Internet-based
initiatives in addition to marketing programs.  The initial relationship in this
new strategic direction was entered into with Bristol-Myers Squibb Company in
which we are working with Bristol-Myers to develop innovative new approaches to
electronic medical education.

REVENUE SOURCES

Our main source of revenue is through client services related to the development
and support of on-line marketing and advertising programs for pharmaceutical and
other healthcare companies. These services typically include the design,
development and management of customized Web sites relating to a particular
pharmaceutical or other health-related product. Client services also include
marketing research, focus group testing and on-line testing of visitors'
preferences. Revenue from client services
<PAGE>

is recognized over the period that the services are performed. Revenue from
support services, principally the management of Web sites that we develop for
our clients, is recognized ratably over the management periods, generally on a
monthly basis. Payments received from clients prior to the performance of client
services are recorded as unearned revenue.

We also provide advertising services involving the sale of advertising space on
Web sites we own, manage or sponsor. These services can be provided separately
or as part of a more comprehensive suite of client services. Advertising
services include banner advertisements, polls, surveys, registration programs,
coupons and other interactive forms of advertising. Revenue from advertising
sales is recognized ratably over the period in which the advertisement is
displayed, if no significant obligations remain. In certain cases, advertising
revenue from the sale of advertising space is related to the delivery of
impressions or click-throughs from pages viewed by visitors to our Web sites. In
these cases, we may guarantee a minimum number of impressions or click-throughs
by visitors over a specific period of time. To the extent that revenue is
related to the number of impressions or click-throughs, we defer recognition of
this revenue until the required impressions or click-throughs are achieved.
Payments received from advertisers prior to displaying their advertisements are
recorded as deferred revenue. Mediconsult does not recognize revenue from barter
transactions with respect to its advertising services.  We recently announced
that effective October 1, 1999 we will no longer sell banner advertising on our
consumer Web sites.  As a result, this source of revenue may decline in future
periods even though we will continue to sell such advertising on our
professional sites such as Physicians' Online.

We also derive revenue from licensing our mediconsult.com content and providing
Web site support to healthcare and other organizations. These client
organizations make our content available to visitors to their Web sites or to
Web sites of their clients. Revenue from content licensing is recognized over
the period of the license. In certain cases, we design and develop these Web
sites. The portion of licensing revenue related to up-front customized design
work is recognized over the period that the work is performed. In certain cases,
we realize additional revenue from management of the Web site or its content.
Revenue from management services is recognized ratably over the period the
services are performed, generally on a monthly basis. We may also retain the
right to place advertising on a Web site that hosts our content.

Although we have certain electronic commerce alliances with merchants of
healthcare-oriented books and products, revenue from these revenue-sharing
arrangements has not been material. Revenue from our share of the proceeds from
electronic commerce partners' sales is recognized by Mediconsult upon
notification from our commerce partners of sales attributable to our Web sites.


MARKETING AND SALES INITIATIVES

In late 1997, we initiated our first significant marketing and advertising
program. The Company was engaged by Novartis Consumer Health Canada to develop a
comprehensive on-line smoking cessation program for its Habitrol brand, focused
on Canadian consumers. We developed the Web site for this program during early
1998, for which we received payment as services were performed. We receive
revenue for maintaining and upgrading this program (beginning with its launch in
June 1998), and receive monthly advertising revenue for referring visitor
traffic to the Habitrol Web site. We are currently expanding the Habitrol
program to provide French and professional healthcare versions of the Web site.

We have also generated revenue from developing programs for a number of branded
pharmaceutical products for Novartis Pharma, the worldwide pharmaceutical
division of Novartis. We are developing the Web sites for these programs and
receiving payment as services are performed. We are developing a custom version
of an electronic medical education product for Bristol-Myers Squibb. We have
also completed assessment programs for Glaxo Wellcome and Astra Merck. The loss
of Novartis or Bristol Myers Squibb as a customer or any changes to the existing
relationships that are less favorable to us, or any significant reduction in
traffic on or through the Web sites that we manage, will materially and
adversely affect our business, financial condition and results of operations.
<PAGE>

To date, our revenue has been generated primarily by our own internal sales
organization, Pharma Marketing, LLC. and, to a lesser extent, by third party
advertising representatives. As of September 30, 1999, we had an internal
marketing, sales and program design organization of 50 professionals, compared
to 28 at June 30, 1999. We believe that we need to further increase the size of
our internal marketing and sales organization in order for us to execute
successfully our growth strategy and, accordingly, we intend to hire additional
marketing and sales professionals in 1999.

To complement our direct sales force, in February 1999, we entered into a
memorandum of agreement outlining the principal terms of a 50/50 joint venture
with CommonHealth LLP, the leading healthcare advertising firm worldwide.
CommonHealth is an affiliate of Ogilvy & Mather and J. Walter Thompson.

In order to enhance our content licensing initiatives and generate additional
revenue, we have entered into marketing alliances with a number of companies and
organizations. These include the healthcare division of IBM, GeoAccess, a
software development company focused on the managed care sector, and the Ontario
Hospital Association, an association of approximately 185 not-for-profit
hospitals.

VISITOR TRAFFIC

To improve the depth and breadth of our medical content and to increase visitor
traffic, we recently completed strategic initiatives to purchase, manage or
sponsor the following Web sites:

     .    PharmInfo.com, a leading Web site providing information on
          pharmaceutical products and clinical trials for pharmacists,
          physicians and consumers. We acquired PharmInfo.com in December 1998,
          in exchange for 100,000 shares of our common stock. The fair value of
          these shares of common stock was $0.8 million, which was capitalized
          and will be amortized over three years.

     .    INCIID.org, a Web site providing information on infertility. In
          February 1999, we entered into an exclusive sponsorship agreement with
          the InterNational Counsel of Infertility Information Dissemination, a
          not-for-profit organization, relating to INCIID.org and granting us
          the sole right to place advertisements on the Web site, to link
          traffic, and to manage the content on the Web site. In connection with
          this agreement, we have committed to pay INCIID $0.5 million per year
          beginning in 1999, for three years in equal quarterly installments, in
          cash or common stock as we determine with respect to each quarter. We
          have paid $375,000 in cash to September 30, 1999.

     .    Cyberdiet.com, a Web site providing tailored nutritional information
          and programs. In May 1999, we completed the acquisition of CyberDiet
          Inc., in exchange for 400,000 shares of Mediconsult common stock. The
          total purchase price, including acquisition costs and assumption of
          accumulated deficit, was $2.8 million. The fair value of shares
          provided as consideration was determined by the market price of the
          shares at the transaction date. The excess of the purchase price over
          net assets acquired was recorded as goodwill and is amortized on a
          straight-line basis over five years.

     .    Heartinfo.org, a leading Web site that provides high quality content
          and tools focused on heart disease and related areas that have
          attracted a large and growing number of visitors to the
          www.heartinfo.com Web site. We acquired Cyber-Tech, Inc., which
          operates Heartinfo.org for consideration of $3.75 million and 267,000
          shares of common stock. The total transaction value, including
          acquisition costs, was $7.6 million. The fair value of shares provided
          as consideration was determined by the market price of the shares at
          the transaction date. The excess of the purchase price over net assets
          acquired was allocated to value of non-competition agreements and to
          goodwill. The non-competition agreements were valued in accordance
          with the terms of the acquisition agreement and are being amortized
          over the life of the underlying employment agreements, which range
          from three to five years. Goodwill is being
<PAGE>

          amortized on a straight-line basis over an estimated useful life of
          five years.

We believe that Mediconsult's Web sites together represent one of the most
highly trafficked consumer healthcare information sites on the Internet.  During
the second quarter, our Web sites attracted 6.2 million visitors who viewed 35.4
million pages. On average, viewers spent 15 minutes per session on
Mediconsult.com's Web sites.

PENDING ACQUISITION

On September 7, 1999, the Company entered into an agreement to acquire the
shares of Physicians' Online, Inc. ("POL"), a provider of an exclusive network
for physicians in addition to on-line medical information and communications.
POL operates a secure, physicians-only environment featuring access to medical
databases, daily medical news, continuing medical education credits, clinical
symposia, e-mail accounts, Internet access, and other services.  Consideration
for the acquisition will be up to 20 million shares of Mediconsult common stock.
The total transaction value at the time of announcement was $180 million,
including the assumption of debt.  The transaction is subject to customary
closing conditions.  The stockholders of Physicians' Online, Inc. and
Mediconsult hold the votes required to approve the merger and have agreed to
vote in favor of the transaction.  In the quarter ended September 30, 1999, the
Company advanced $10.1 million to Physicians' Online, Inc.  This advance bears
interest at rates between 12% and 14%.

STOCK OPTIONS AND WARRANTS

Stock options granted to employees are expensed over their vesting period, based
on their fair value at the date of grant, under Statement of Financial
Accounting Standards No. 123 "ACCOUNTING FOR STOCK-BASED COMPENSATION." As more
fully described below in "Results of Operations," we have recorded compensation
expense in connection with the vesting of stock options during the nine month
periods ended September 30, 1999 and 1998, as well as deferred compensation
expense for the value of options granted that were not vested as of such dates.
We recorded expense of $0.52 million and $0.03 million regarding the fair value
of stock options granted for the three months ended September 30, 1999 and 1998
respectively. In the nine months ended September 30, 1999, we recorded an
expense of $1.06 million, compared to $0.10 million for the corresponding period
in the prior year.

Pursuant to an agreement dated July 28, 1998 with Arnhold and S. Bleichroeder,
Inc. to provide us with investment advisory services, we have issued to this
firm 100,000 shares of our common stock and warrants to purchase an aggregate of
400,000 shares of common stock with an exercise price of $1.22 per share, which
was the closing price of our common stock on the contract date. Of this amount,
warrants for 200,000 shares of common stock were delivered upon initial filing
of a prospectus and warrants for 200,000 shares of common stock are deliverable
in 2000, if certain conditions are met. Delivery of the warrants on April 6,
1999 resulted in the recognition of an expense in the statement of operations
equal to the fair value of the warrants, which was estimated at $1.1 million.
In addition, we recognized $0.2 and $0.6 of expense for the warrants vesting
during the quarter and six months ended September 30, 1999, respectively.

On February 26, 1999, the Company sold in a private placement an aggregate of
506,329 shares of newly designated voting senior preferred stock and warrants
exercisable for five years to purchase 224,000 shares of the senior preferred
stock to Nazem & Company IV, L.P. Transatlantic Venture Fund C.V. (a joint
venture of Nazem & Company and Banque Nationale de Paris) and certain other
individual investors, for an aggregate of $ 3.2 million. The purchase price and
the conversion price of the senior preferred stock and exercise of the warrants
$6.32 per share.  The shares of the senior preferred stock are convertible at
the option of the holder into an equal number of shares of common stock, subject
to adjustment, and will be automatically converted into an equal number of
shares of common stock upon closing of the Company's closing of the public
offering.  The senior preferred stock contains a redemption provision whereby
the holder has the option to receive $6.32 per share, plus declared and unpaid
dividends, at any time after February 25, 2003.  In addition, the Company has
recognized a senior preferred stock dividend of approximately $0.86 million.
Such amount represents the intrinsic value of the beneficial conversion feature
using the conversion terms that are most beneficial to
<PAGE>

the holders. During April 1999, all shares of senior preferred stock and
accumulated dividends were converted into an equal number of common shares.

RESULTS OF OPERATIONS

REVENUE.  Revenue consists of fees received for the design, development and
implementation of on-line marketing and advertising programs, including Web site
development and implementation, advertising services, licensing our content and
Web site support. Revenue was $2.4 million for the quarter ended September 30,
1999 compared to $0.24 million for the quarter ended September 30, 1998. Revenue
was $3.72 million for the nine months ended September 30, 1999 and $0.66 million
for the nine months ended September 30, 1998. The period-to-period growth in
revenue was primarily attributable to an increase in (i) the number of visits to
our Web sites, (ii) the number of clients, (iii) the number of marketing and
advertising programs developed and implemented for those clients, and (iv) the
acquisition of the Pharminfo.com, CyberDiet.com and HeartInfo.org web sites.

PRODUCT AND CONTENT DEVELOPMENT.  Product and content development costs include
expenses we incur to develop, enhance, manage, monitor and operate our Web
sites. These costs consist primarily of salaries and fees paid to employees and
consultants to develop and maintain the software and information contained on
the Mediconsult.com Web sites. For the quarter ended September 30, 1999, these
costs were $2.37 million and for the quarter ended September 30, 1998, these
costs were $0.40 million. These costs related primarily to the development of
healthcare content and interactive services. Product and content development was
$4.64 million for the nine months ended September 30, 1999 and $0.91 million for
the nine months ended September 30, 1998. The increase in 1999 expenses compared
to 1998 reflects increased staffing required to meet the expanding volume of
business that the Company has secured.

MARKETING, SALES AND CLIENT SERVICES.  Marketing, sales and client services
costs include expenses we incur to obtain and maintain client relationships.
These costs include salaries and fees paid to employees and consultants, and
programming costs. For the quarter ended September 30, 1999, these costs were
$6.09 million, consisting primarily of costs associated with the development and
implementation of specific client marketing programs and of new prototype
marketing and advertising programs. Also included in marketing, sales and client
services are all costs associated with Pharma Marketing LLC ("Pharma"), an
entity organized to perform the sales and marketing operations of the Company
and operate solely on behalf of the Company. During the quarter ended September
30, 1999, such Pharma expenses amounted to  $3.32 million.  For the quarter
ended September 30, 1998, marketing, sales and client services costs were $0.23
million. Marketing, sales and client services expense was $7.66 million for the
nine months ended September 30, 1999 and $0.91 million for the nine months ended
September 30, 1998. The increase in marketing, sales and client services
reflects an expansion of the Company's sales and marketing activities including
additional staff and new promotion and advertising campaigns, and the costs
associated with Pharma.

GENERAL AND ADMINISTRATIVE EXPENSES.  General and administrative expenses
consist primarily of salaries and related costs for general corporate functions,
including finance, accounting and legal expenses, and fees for other
professional services. For the quarter ended September 30, 1999, general and
administrative expenses were $1.85 million and for the quarter ended September
30, 1998 these costs were $0.18 million. The increase in general and
administrative expenses was primarily attributable to increased salaries and
related expenses associated with hiring additional personnel to support the
growth of our operations. General and administrative expense was $3.33 million
for the nine months ended September 30, 1999 and $0.49 million for the nine
months ended September 30, 1998. General and administrative expenses increased
as the Company's operations grew. The increase in expense also reflects the
additional professional and reporting costs now that the Company is listed on
NASDAQ.

DEPRECIATION AND AMORTIZATION EXPENSE. Depreciation and amortization expense
reflects depreciation of tangible assets and software was $0.22 million and
amortization of intangible assets was $0.67 million, for the quarter ended
September 30, 1999, compared to $0.04 million and $nil respectively for the
corresponding period in 1998. Depreciation of tangible assets and software was
$0.39 million and
<PAGE>

amortization of intangible assets was $1.00 million for the nine months ended
September 30, 1999, compared to $0.21 million and $nil for the nine months ended
September 30, 1998.

The increase in depreciation expense reflects the increased investment in
capital assets as now we have expanded our office facilities and have installed
Web and network servers. The increase in amortization expense is due to the
acquisition of Pharminfo.Net in December 1998, the acquisition of CyberDiet,
Cyber-Tech in May 1999 and June 1999 respectively. Intangible value associated
with these transactions, represented by the excess of purchase price over net
tangible assets, is being amortized over three to five years.

FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES.  We recorded compensation expense in
connection with the vesting of employee stock options of $0.52 million during
the quarter ended September 30, 1999, and $0.03 million during the quarter ended
September 30, 1998. Compensation expense for the fair value of employee options
was $1.06 million for the nine months ended September 30, 1999 and $0.10 million
for corresponding period in the prior year. Compensation expense represents the
amortization of deferred compensation, which is measured based on the fair value
of the options granted. These amounts are amortized over the vesting period of
the applicable options. We have recorded deferred compensation for the value of
options granted that are not yet vested of $8.33 million as of September 30,
1999.

FAIR VALUE OF OPTIONS AND WARRANTS GRANTED TO OTHERS. We recorded expense in
connection with the vesting of warrants to Arnhold & S. Bleichroeder Inc.
Compensation expense was $1.71 million for the nine months ended September 30,
1999. There was no corresponding expense in 1998.

INTEREST INCOME. During the quarter ended September 30, 1999, the company earned
interest income of $0.59 million as compared to $nil in the quarter ended
September 30, 1998. Interest income in the nine months ended September 30, 1999
was $1.17 million compared to $nil in the corresponding period in the prior
year. The increase in interest income over the prior year reflects increased
cash on hand as a result of the net proceeds from the offering that was
completed in April of this year.

FACTORS THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE
PROJECTED

The information and data contained in this quarterly report includes all
necessary adjustments, consisting only of normal recurring adjustments necessary
for fair presentation of this data. The results of operations for any quarter
are not necessarily indicative of the results of operations for any future
period.

We have a limited operating history upon which to evaluate our business and
predict revenue and planned operating expenses. Our quarterly operating results
may vary significantly in the foreseeable future due to a variety of factors,
many of which are outside of our control. The timing of advertising sales is one
of the most significant factors affecting quarterly results. The time between
the date of initial contact with a potential advertiser and the execution of a
contract with the advertiser typically ranges from six weeks for smaller
agreements to nine months for larger agreements. These contracts are also
subject to delays over which we have little or no control, including customers'
budgetary constraints, their internal acceptance reviews, whether or when
regulatory approval of their products is given by the FDA or other regulatory
authority, the possibility of cancellation or delay of projects by advertisers
and any post-approval actions taken by the FDA or other regulatory authority,
including product recalls. During the selling process, we may expend substantial
funds and management resources and yet not obtain adequate advertising revenue.
Once a contract is executed, a significant portion of our revenue is derived
from customized Web site development and implementation projects, rather than
from recurring fees. As a result, we cannot predict with certainty when we will
perform the work necessary to receive payment for these projects. In addition,
traffic levels on Web sites have typically fluctuated during the summer, and
during year-end and holiday periods, and we could experience a decrease in
visitor traffic to our Web sites during these periods.

LIQUIDITY AND CAPITAL RESOURCES
<PAGE>

Since inception, we have financed our operations primarily through the placement
of equity securities and advances from our principal stockholder. In April 1999,
we received net proceeds of $58.1 million from a public offering of equity
securities. Issue costs associated with this offering, which have been offset
against the net proceeds of the offering, were $1.1 million. As of September 30,
1999, we had $33.9 million in cash and cash equivalents.

We have incurred substantial costs to design, develop and implement Internet-
based marketing and advertising programs for our clients, to build brand
awareness and to grow our business. As a result, we have incurred operating
losses and negative cash flows from operations in each quarter since we
commenced operations. As of September 30, 1999, we had an accumulated deficit of
$23.3 million. These losses have been partially funded through private and
public placements of equity securities.

To date, we have experienced negative cash flows from operating activities. For
the nine months ended September 30, 1999 and September 30, 1998, net cash used
in operating activities was $10.3 million and $1.9 million, respectively. Net
cash used reflected several factors, including (1) increased operating expenses
as our business volume increased; (2) a higher level of work in progress due to
growth of marketing and advertising program revenue; and (3) increases in
accounts payable and accrued expenses, which partially offset the increases. For
the nine months ended September 30, 1999, the increase in net cash used in
operating activities was primarily attributable to our net operating loss of
$14.9 million. The net loss for the quarter was partially offset by certain non-
cash items of $4.6 million in the aggregate, comprised primarily of deferred
compensation expense of $2.8 million related to stock options granted to
employees and warrants, and depreciation and amortization of $1.4 million.

For the nine months ended September 30, 1999, net cash used in investing
activities was $15.7 million compared to $0.03 million in the corresponding
period in 1998. In the first nine months of 1999, $1.5 million was used to
acquire capital assets, primarily the acquisition of computer equipment and
software, $4.1 million was used to acquire the issued capital stock of
CyberDiet, Inc. and Cyber-Tech, Inc. and $10.1 million was advanced to
Physicians' Online, Inc.

For the nine months ended September 30, 1999, net cash provided by financing
activities was $61.5 million. Net cash proceeds from financing activities for
the first nine months of the year were primarily attributable to the April
public offering of equity securities.

As of September 30, 1999, we had no material capital commitments outstanding,
although we expect to undertake further capital spending as we establish offices
and other facilities in the United States and Canada.

In connection with our joint venture with CommonHealth, we expect to advance
approximately $0.3 million to the joint venture as our share of its initial
capitalization. Under our agreement with CommonHealth, we may borrow this amount
from CommonHealth. If we do borrow this amount, we must repay it from 25% of our
portion of the net profits of the joint venture, if any, and in any event within
three years from the formation of the joint venture or sooner if the joint
venture is terminated.

In connection with our sponsorship and management of INCIID.org, we have
committed to pay INCIID.org $0.5 million per year for three years, beginning in
1999.  The payments are made in equal quarterly installments, in cash or common
stock as we determine with respect to each quarter. In the nine months ended
September 30, 1999 we had advanced $0.38 million to INCIID.

Our ability to generate significant revenue is uncertain. We incurred net losses
of approximately $8.9 million for the quarter ended September 30, 1999. We
expect losses from operations and negative cash flow to continue for the
foreseeable future, and at least through the year 2000, as a result of our
expansion plans and our expectation that operating expenses will increase
significantly in the next several years. The rate at which these losses will be
incurred may increase from current levels. Although we have experienced revenue
growth in recent periods, our revenue may not remain at its current level or
increase in the future. If our revenue does not increase and if our spending
levels are not adjusted accordingly,
<PAGE>

we may not generate sufficient revenue to achieve profitability, which would
have a material, adverse effect on our business, financial condition and results
of operations. Even if we achieve profitability, we may not sustain or increase
profitability on a quarterly or annual basis in the future.

Our working capital requirements depend on numerous factors. We have experienced
a substantial increase in our expenditures since inception, consistent with
growth in our operations and staffing, and anticipate that this will continue
for the foreseeable future. We anticipate incurring additional expenses to
increase our marketing and sales efforts, for content development and for
technology and infrastructure development. Additionally, we will continue to
evaluate possible investments in businesses, products and technologies, the
expansion of our marketing and sales programs and more aggressive brand
promotions.

If we experience a shortfall in revenue in relation to expenses, or if our
expenses precede increased revenue, our business, financial condition and
results of operation and could be materially and adversely affected.

We currently anticipate that available cash resources combined with the net
proceeds from the April equity offering and revenue from client contracts will
be sufficient to meet our anticipated needs for working capital and capital
expenditures through December 31, 2000. We may need to raise additional funds,
however, in order to fund more rapid expansion, to develop new or enhance
existing services or products, to respond to competitive pressures or to acquire
complementary products, businesses or technologies. There can be no assurance
that any required additional financing will be available on terms favorable to
us, or at all. If additional funds are raised by the issuance of equity
securities, stockholders may experience dilution of their ownership interest and
these securities may have rights senior to those of the holders of the common
stock. If additional funds are raised by the issuance of debt, we may be subject
to certain limitations on our operations, including limitations on the payment
of dividends. If adequate funds are not available or are not available on
acceptable terms, we may be unable to fund our expansion, successfully promote
our brand name, take advantage of acquisition opportunities, develop or enhance
services or respond to competitive pressures, any of which could have a material
adverse effect on our business, financial condition and results of operations.

Although a significant portion of our revenue is derived from activities
conducted outside the United States, fees paid to us have been and are expected
to continue to be paid in U.S. dollars. However, a substantial portion of our
payroll is paid and it is expected that rent under leases of office facilities
outside the United States will be paid, in currencies other than U.S. dollars.
Because our financial results are reported in U.S. dollars, they are affected by
changes in the value of the various foreign currencies in which we make payments
in relation to the U.S. dollar. We do not cover known or anticipated currency
fluctuation exposures through foreign currency exchange option or forward
contracts. The primary currency for which we have foreign currency exchange rate
exposure is the Canadian dollar. Our financial instruments, including cash,
accounts receivable, accounts payable and accrued liabilities are carried at
cost which approximates their fair value because of the short-term maturity of
these instruments.

YEAR 2000

Some computers, software and other equipment include programming code in which
calendar year data is abbreviated to only two digits. As a result of this design
decision, some of these systems could fail to operate or fail to produce correct
results if "00" is interpreted to mean 1900, rather than 2000. These problems
are widely expected to increase in frequency and severity as the year 2000
approaches and are commonly referred to as the year 2000 problem. Significant
uncertainty exists in the software and Internet industries concerning the scope
and magnitude of problems associated with the year 2000 problem.

INTERNAL INFRASTRUCTURE.  We believe that we have identified substantially all
of the major computers, software applications and related equipment used in
connection with our internal operations to determine if they will be year 2000
compliant. Based on our assessment to date, we presently believe that our
internal computer systems are year 2000 compliant. Nevertheless, we continue to
test our internal systems, on
<PAGE>

a system by system basis, as we complete our ongoing compliance efforts with
respect to non-information technology systems.

SYSTEMS OTHER THAN INFORMATION TECHNOLOGY SYSTEMS.  In addition to computers and
related systems, the operation of our offices and facilities equipment, such as
fax machines, photocopiers, telephone switches, security systems, elevators and
other common devices may be affected by the year 2000 problem. We have completed
the assessment of the potential effect of, and costs of remediating, any year
2000 problem related to this equipment and estimate that our total cost of
completing any required modifications, upgrades or replacements of these
internal systems will not be material.

SUPPLIERS.  We have been gathering information from and have initiated
communications with our service and content providers to identify and, to the
extent possible, resolve issues involving the year 2000 problem. However, we
have limited or no control over the actions of our service and content
providers. Thus, while we expect that we will be able to resolve any significant
year 2000 problems with our systems, we cannot guarantee that our service and
content providers will resolve any or all year 2000 problems with their systems
before the occurrence of a material disruption to our business. Any failure of
these third parties to resolve year 2000 problems with their systems in a timely
manner could have a material adverse effect on our business, financial condition
and results of operations.

MOST LIKELY CONSEQUENCES OF YEAR 2000 PROBLEMS.  We expect to identify and
resolve all year 2000 problems that could materially adversely affect our
business, financial condition or operating results. However, we believe that it
is not possible to determine with complete certainty that all year 2000 problems
affecting us have been identified or corrected. The number of devices that could
be affected and the interactions among these devices are simply too numerous. In
addition, we cannot accurately predict how many failures related to the year
2000 problem will occur or the severity, duration or financial consequences of
such failures. As a result, we could possibly suffer the following consequences:

     .    a significant number of operational inconveniences and inefficiencies
          for us, our service and content providers and our visitors that may
          divert our time and attention and financial and human resources from
          our ordinary business activities; and

     .    a lesser number of serious system failures that may require
          significant efforts by us, our service and content providers or our
          visitors to prevent or alleviate material business disruptions.

In addition, there can be no assurance that governmental agencies, utility
companies, Internet access companies, third party service providers and others
outside of our control will be year 2000 compliant. The failure of these
entities to be year 2000 compliant could result in a systemic failure beyond our
control, such as a prolonged Internet, telecommunications or electrical failure,
which could also prevent us from operating our business, prevent visitors from
accessing our Web sites, or change the behavior of consumers accessing our Web
sites, which could have a material adverse effect on our business, financial
condition and results of operations.

CONTINGENCY PLANS.  As discussed above, we are engaged in an ongoing year 2000
assessment. We have not yet developed any contingency plans. The results of our
year 2000 simulation testing and the responses received from third party vendors
and service providers will be taken into account in determining the nature and
extent of any needed contingency plans.  To date, the costs of this ongoing
assessment have not been material.

FORWARD LOOKING STATEMENTS

When used in this Quarterly Report on Form 10-Q, in documents incorporated
herein and elsewhere by us from time to time, the words "believes,"
"anticipates," "expects" and similar expressions are intended to identify
forward-looking statements concerning our business operations, economic
performance and financial condition, including in particular, our business
strategy and means to implement the strategy, our objectives, the amount of
future capital expenditures required, the likelihood of our success in
developing and introducing new products and expanding the business, and the
timing of the introduction of new and modified products or services. For those
statements, we claim the protection of the safe harbor for forward looking
statements contained in the Private Securities Litigation Reform Act of 1995.
These forward looking statements are based on a number of assumptions and
Estimates which are inherently subject to significant risks and uncertainties,
many of which are beyond our control and reflect future business decisions which
are subject to change. A variety of factors could cause actual results to differ
materially from those anticipated in our forward-looking statements, including
the following factors: (a) those set forth in our Form 10-KSB/A for the period
ended December 31, 1998, incorporated herein by reference, and elsewhere herein;
and (b) those set forth from time to time in our press releases and reports and
other filings made with the Securities and Exchange Commission. We caution that
such factors are not exclusive. Consequently, all of the forward-looking
statements made in this document are qualified by these cautionary statements
and readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this Quarterly Report on Form 10-
Q. We undertake no obligation to publicly release the results of any revisions
of such forward-looking statements that may be made to reflect events or
circumstances after the date hereof, or thereof, as the case may be, or to
reflect the occurrence of unanticipated events.


PART II. OTHER INFORMATION

ITEM 1.  PENDING LEGAL PROCEEDINGS

There are no pending legal proceedings in which we are a party, and we are not
aware of any threatened legal proceedings involving it.

ITEM 2.  CHANGES IN SECURITIES

On September 7, 1999, we acquired a 35% interest in Pharma Marketing, LLC in
exchange for cash of $3.3 million, of which $1.65 million was reinvested in
Mediconsult in exchange for the issuance of 200,000 of our common shares.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 6.  EXHIBITS AND REPORTS FILED ON FORM 8-K

There are no Exhibits filed with this current report on Form 10-Q.

On September 3, 1999, the Company amended its report on Form 8-K, pursuant to
Items 2 and 7, filed June 29, 1999 regarding its acquisition of Cyber-Tech, Inc.

On September 10, 1999, the Company filed a report on Form 8-K, pursuant to Item
5 of such Form, regarding its acquisition of Physicians' Online, Inc.


                                  SIGNATURES


                              Mediconsult.com, Inc.



Date: March 30, 2000          Signature: /s/ E. Michael Ingram
                                         E. Michael Ingram
                                         Chief Financial Officer